Ocular Therapeutix Inc. (OCUL)
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OCUL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.23B
- EPS (TTM)
- -$1.44
- Dividend yield
- None
- 52-week range
- 5.54 – 16.44
- Day range
- 5.54 – 5.95
- Volume / Avg
- 2.89M / 3.03M
- Beta
- —
- Shares outstanding
- 220.02M
52-week range
OCUL stock today
Ocular Therapeutix (OCUL) closed at $5.57 on Nov 20, down 4.95% (-$0.29), versus the S&P 500's 3.70% decline. Shares are 66.1% below their 52-week high of $16.44, set on Dec 8, 2025 and 0.5% above the 52-week low of $5.54, near the bottom of the past year's range. OCUL is down 54.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.5%.
Ocular Therapeutix has posted a net loss over the last twelve months (EPS of -$1.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ocular Therapeutix
Company profileOcular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Pravin U. Dugel M.D.
- Headquarters
- Bedford, MA
- Employees
- 325
- IPO year
- 2014
- Website
- ocutx.com
Financial highlights
Full financialsIn fiscal 2025, Ocular Therapeutix generated $52.0 million in revenue, down 18.5% from fiscal 2024, the first decline in the 14 years shown. Ocular Therapeutix reported a net loss of $265.9 million, compared with a loss of $193.5 million a year earlier. Gross margin was 87.3% (down from 91.2%) and operating margin -519.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M |
| Growth | -18.47% | +9.03% | +13.49% | +18.32% | +150.08% |
| Net income | $-265.94M | $-193.51M | $-80.74M | $-71.04M | $-6.55M |
| EPS (diluted) | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$25.73+361.94%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.37 vs $-0.36
- Surprise
- -2.78%
OCUL news
All OCUL news- Ocular Therapeutix Grants Inducement Stock Awards To Tiffany HowardNasdaq
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Tx (OCUL) Q3 2026 Earnings Call TranscriptNasdaqOCUL, MOG.A
- Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028Seeking Alpha
- Ocular Therapeutix, Inc. Reports Third Quarter 2026 Financial Results and Cash Balance of $530.6 millionNasdaq
- Why is Ocular Therapeutix stock sliding today?Investing.com
- Ocular Therapeutix GAAP EPS of -$0.42 misses by $0.06, revenue of $12.88M misses by $1.42MSeeking Alpha
- Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswire
Ocular Therapeutix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs OCUL |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs OCUL |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs OCUL |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs OCUL |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs OCUL |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs OCUL |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs OCUL |
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs OCUL |
Indexes, lists and sector
Ocular Therapeutix stock FAQ
What is Ocular Therapeutix's stock price today?
OCUL last traded at $5.57 as of Nov 20, 4:00 PM EST, down 4.95% on the day. Prices are delayed at least 15 minutes.
Who is Ocular Therapeutix's CEO?
Dr. Pravin U. Dugel M.D. is the chief executive officer of Ocular Therapeutix Inc., which has about 325 employees.
What is the OCUL 52-week high?
The 52-week high for OCUL is $16.44 and the 52-week low is $5.54. The stock is currently 66.1% below its high.